StockData
Climb Bio, Inc. logo

Climb Bio, Inc. (CLYM) stock

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$9.78−0.16 (-1.61%)

Close on Nov 17, 2026Market cap $561.73MP/E –Yield –

Climb Bio cash

Cash and short-term investments held at the end of each period.

Climb Bio's cash was $183.12M at Jun 30, 2026. For fiscal 2025 it was $160.70M, up 6.5% from the year before. The highest annual figure on record is $161.40M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$160.70M+6.5%
FY2024Dec 31, 2024$150.92M+41.3%
FY2023Dec 31, 2023$106.80M-13.6%
FY2022Dec 31, 2022$123.60M-23.4%
FY2021Dec 31, 2021$161.40M+687.8%
FY2020Dec 31, 2020$20.49M-3.5%
FY2019Dec 31, 2019$21.22M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$183.12M+116.2%
Q1 FY2026Mar 31, 2026$109.56M+11.7%
Q4 FY2025Dec 31, 2025$160.70M+6.5%
Q3 FY2025Sep 30, 2025$86.90M-55.1%
Q2 FY2025Jun 30, 2025$84.70M-62.0%
Q1 FY2025Mar 31, 2025$98.06M-6.6%
Q4 FY2024Dec 31, 2024$150.92M+41.3%
Q3 FY2024Sep 30, 2024$193.35M+80.0%
Q2 FY2024Jun 30, 2024$223.14M+117.4%
Q1 FY2024Mar 31, 2024$105.03M-4.0%
Q4 FY2023Dec 31, 2023$106.80M-13.6%
Q3 FY2023Sep 30, 2023$107.43M-12.4%
Q2 FY2023Jun 30, 2023$102.63M-16.5%
Q1 FY2023Mar 31, 2023$109.37M-27.0%
Q4 FY2022Dec 31, 2022$123.60M-23.4%
Q3 FY2022Sep 30, 2022$122.62M-16.0%
Q2 FY2022Jun 30, 2022$122.95M+23.6%
Q1 FY2022Mar 31, 2022$149.90M+212.9%
Q4 FY2021Dec 31, 2021$161.40M+687.8%
Q3 FY2021Sep 30, 2021$146.02M+1050.7%
Q2 FY2021Jun 30, 2021$99.48M+552.8%
Q1 FY2021Mar 31, 2021$47.91M+125.8%
Q4 FY2020Dec 31, 2020$20.49M–
Q3 FY2020Sep 30, 2020$12.69M–
Q2 FY2020Jun 30, 2020$15.24M–
Q4 FY2019Dec 31, 2019$21.22M–

More Climb Bio figures

See a number that looks wrong?